Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office will issue U.S. Patent Number 12,370,244 on July 29, 2025, covering key aspects of the company’s breast cancer vaccine technology. The patent protects novel methods of immunizing patients against breast cancer by administering an immunogenic composition containing human alpha-lactalbumin protein-a protein typically found in breast tissue during lactation but also expressed in certain breast cancers, making it an attractive target for immunoprevention strategies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Positive Outlook for Anixa Biosciences: Patent Secures Ovarian Cancer Vaccine and Promising CAR-T Therapy Progress
- Anixa announces issuance of additional USPTO for ovarian cancer vaccine tech
- Positive Outlook for Anixa Biosciences: Promising Cancer Treatment Trials Justify Buy Rating
- Anixa initiates dosing in fourth cohort of ovarian cancer CAR-T trial
- Anixa Biosciences announces poster presentation on Ovarian cancer CAR-T trial